BioSpace News Archive

Clario and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE:8MV) (“BioHarvest” or “the Company”) has unveiled a plan to enter new consumption categories where VINIA will be incorporated to create unique and highly differentiated products for the Food & Beverage and the Nutraceuticals markets.

Zymo Research, a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040.

Integra LifeSciences Holdings Corporation announced the appointment of Lea Daniels Knight as executive vice president and chief financial officer, effective June 28, 2023.

Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment for two individuals, the Chief Medical Officer, Vojislav Vukovic, and the Principal Accounting Officer and Principal Financial Officer, Sandra Pennell.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract in the form of a production facility cotenancy agreement negotiated by the Issuer, pay current filing, regulatory, and finder fees in connection with the offering, and for general working capital purposes.

IGM Biosciences, Inc. announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering and concurrent private placement.

Azitra, Inc. announced the closing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $7,500,000, before deducting underwriting discounts and offering expenses.

Innovation Pharmaceuticals announced the United States Patent and Trade Office, on June 6, 2023, granted a patent, “Host Defense Protein Mimetics for Prophylaxis and/or Treatment of Inflammatory Diseases of the Gastrointestinal Tract,” and also recently issued a Notice of Allowance for the patent application, “Arylamide Compounds For Treatment Of Viral Infections.”